Skip to main content
. 2015 Aug 7;21(29):8836–8847. doi: 10.3748/wjg.v21.i29.8836

Table 3.

Univariate and multivariate analyses in colorectal cancer tissue specimens (n = 712)

Variables Overall survival
Disease-free survival
HR (95%CI) P value HR (95%CI) P value
Univariate analyses
Sex (male vs female) 0.84 (0.58-1.23) 0.376 0.86 (0.63-1.18) 0.342
Age (≥ 60 yr vs < 60 yr) 1.24 (0.85-1.80) 0.259 0.95 (0.69-1.30) 0.734
TNM stage (IV/III vs II/I) 3.11 (2.06-4.70) < 0.001 2.37 (1.72-3.27) < 0.001
Differentiation (poor/mucinous adenocarcinoma vs well/moderate) 1.54 (0.93-2.55) 0.094 1.33 (0.85-2.08) 0.219
Position (rectal vs colon) 0.56 (0.38-0.83) 0.003 0.92 (0.66-1.23) 0.506
CEA (≥ 5 ng/mL vs < 5 ng/mL) 1.97 (1.36-2.85) < 0.001 1.63 (1.19-2.21) 0.002
CA19-9 (≥ 37 U/mL vs < 37 U/mL) 2.27 (1.50-3.42) < 0.001 1.89 (1.31-2.72) 0.001
NLK (++/+++ vs -/+) 2.19 (1.44-3.35) < 0.001 2.71 (1.86-3.94) < 0.001
Postoperative radiochemotherapy (yes vs no) 2.42 (1.30-4.51) 0.005 2.69 (1.60-4.50) < 0.001
Multivariate analyses
TNM stage (IV/III vs II/I) 3.02 (1.99-4.59) < 0.001 2.34 (1.70-3.22) < 0.001
Differentiation (poor/mucinous adenocarcinoma vs well/moderate) 1.78 (1.06-2.98) 0.029 1.45 (0.94-2.24) 0.091
Position (rectal vs colon) 0.49 (0.33-0.72) < 0.001 0.80 (0.59-1.08) 0.143
CEA (≥ 5 ng/mL vs < 5 ng/mL) 1.56 (1.04-2.35) 0.032 1.31 (0.95-1.81) 0.099
CA19-9 (≥ 37 U/mL vs < 37 U/mL) 1.54 (0.99-2.41) 0.058 1.76 (1.24-2.49) 0.002
NLK (++/+++ vs -/+) 2.57 (1.66-3.98) < 0.001 1.96 (1.40-2.74) < 0.001
Postoperative radiochemotherapy (yes vs no) 1.04 (0.50-2.16) 0.921 1.64 (0.93-2.92) 0.090

CA19-9: Cancer antigen 19-9; CEA: Carcinoembryonic antigen; CI: Confidence interval; HR: Hazard ratio; NLK: Nemo-like kinase; TNM: Tumor-node-metastasis.